BiOkuris’ Post

⚡228% superior analgesic effect!⚡ Speaking of synergies... both fungal #chitinglucan and #NCFM have already demonstrated significant effects on pain reduction individually; now, their combination is even more impressive. I can't wait for our ongoing clinical trial, Vitabiotic, to confirm these findings with BK002! This superior pain reduction could be game-changing for IBS patients! #synbiotic #IBS #IFF #BiOkuris

Novel squid-inspired #gastrointestinal capsule enables macromolecular #drug delivery MIT and Novo Nordisk researchers have developed an #ingestible #capsule system that could enable oral delivery of #medications typically requiring injection, such as insulin and therapeutic proteins. Read more https://lnkd.in/eiUQpBhS

Have you faced challenges with using traditional PEGs for bioconjugation? We have you covered. Uniform, single molecular weight, highly pure dPEG(R) is what you have been waiting for. The dPEGs or uniform PEGs from Vector Laboratories can be used to further optimize the PC and adsorption, distribution, metabolism, elimination, and toxicity (ADMET) properties of a therapeutic to achieve targeting, solubility, and stability requirements. Learn more here: https://bit.ly/4cEjKTA #VectorLaboratories #Bioconjugation #BioDesign #Biopharma

🟣 #LNPs, #mRNA, #RiboGreenAssay | 𝗛𝗮𝘀 𝗧𝗿𝗶𝘁𝗼𝗻 𝗫-𝟭𝟬𝟬 𝗳𝗶𝗻𝗮𝗹𝗹𝘆 𝗳𝗼𝘂𝗻𝗱 𝗮𝗻 𝗲𝗰𝗼-𝗳𝗿𝗶𝗲𝗻𝗱𝗹𝘆 𝗿𝗲𝗽𝗹𝗮𝗰𝗲𝗺𝗲𝗻𝘁? 𝚃𝚑𝚎 𝚜𝚎𝚊𝚛𝚌𝚑 𝚏𝚘𝚛 𝚊 𝚖𝚘𝚛𝚎 𝚎𝚌𝚘-𝚏𝚛𝚒𝚎𝚗𝚍𝚕𝚢 𝚊𝚗𝚍 𝚑𝚞𝚖𝚊𝚗-𝚜𝚊𝚏𝚎 𝚊𝚕𝚝𝚎𝚛𝚗𝚊𝚝𝚒𝚟𝚎 𝚝𝚘 𝚃𝚛𝚒𝚝𝚘𝚗 𝚇-𝟷𝟶𝟶 𝚑𝚊𝚜 𝚕𝚎𝚍 𝚝𝚘 𝚒𝚗𝚝𝚎𝚛𝚎𝚜𝚝𝚒𝚗𝚐 𝚏𝚒𝚗𝚍𝚒𝚗𝚐𝚜. 📘 𝗔𝗶𝗺: 🔍 Evaluate less harmful surfactants (Brij 93, Zwittergent 3–14, and Tween 20) as replacements for Triton X-100 in the RiboGreen assay, which measures mRNA concentration and encapsulation efficiency (EE%) in lipid nanoparticles (LNPs). 📊 𝗞𝗲𝘆 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀: 🧬 Zwittergent 3–14 and Tween 20, especially at high concentrations (0.5%), matched the effectiveness of Triton X-100 in releasing mRNA from LNPs across three different mRNA-LNP formulations. Notably, Tween 20 outperformed others across all tested concentrations (0.0025%, 0.01%, 0.1%, and 0.5%), demonstrating potent solubilizing capabilities for diverse LNP formulations. 📌 𝗧𝗮𝗸𝗲 𝗛𝗼𝗺𝗲 𝗠𝗲𝘀𝘀𝗮𝗴𝗲: 🌍 Tween 20 emerges as a promising, environmentally friendly alternative to Triton X-100, enhancing the accuracy of mRNA quantification and EE% in the RiboGreen assay. This substitution not only supports more sustainable practices but also could improve the identification of challenging mRNA-LNP formulations and accurate dosing in research and therapeutic applications. 𝚙𝚞𝚋𝚕𝚒𝚜𝚑𝚎𝚍 𝚒𝚗 European Journal of Pharmaceutics and Biopharmaceutics, 28.10.2024. Check here for more: https://lnkd.in/eHH6GvbC Thank you to the authors, @David Schultz, Rasmus Dithmar Münter, Alex Masi Cantín, Paul Kempen, Nadin Jahnke, @Thomas Andresen, Jens Bæk Simonsen, Andrew Urquhart. What do you think about this advancement? Drop your thoughts below!

The pharmacokinetic and safety/tolerability data on lead clinical asset SFX-01 from our Ph1b healthy volunteer study has just been published online in the November edition of peer reviewed journal, Advances in Therapy. 💊 SFX-01 was well tolerated 💊 PK properties of the SFX-01 tablet formulation were in line with expectations 💊 Levels of sulforaphane and metabolites were in the range where biological activity is observed.   Helen Kuhlman, TheraCryf’s CBO, commented: “Our study is a definitive examination of sulforaphane’s pharmacokinetics from our proprietary enteric coated tablet and provides a detailed analysis of the delivery and handling of sulforaphane from SFX-01 tablets by the body.”   See the article here: https://lnkd.in/eGQz8bm8

🔬 Dive Into #AntibodyDrugConjugate #Pharmacokinetics With Our Advanced Immunoassay (#ELISA) And Mass Spectrometry (#LCMS) Capabilities 🔍 ⚖️ Achieve Efficacy & Safety: Balance The Scales With Comprehensive #PK Analysis And #DrugDrugInteraction Profiling, Securing Your Transition From Research To #ClinicalTrials  📊 Review #Biodistribution & Catabolism: Direct The Progression From #InVitro #Potency Assays To #InVivo Tissue Distribution, Shaping Therapeutic Strategies For Superior Patient Outcomes  🛠️ Assess Linker Stability & Deconjugation: Reveal The Resilience Of ADC #Linkers Across Varied #Biological Systems, Customizing Precise Human PK Dosing Regimens 💡Partner With NorthEast Biolab For One-Stop #Bioanalytical Expertise In ADC PK And Beyond. Let’s Embark On Your #DrugDevelopment Voyage As We Unravel The Complexities Of ADCs To Forge Pathbreaking Treatments! https://lnkd.in/dw2ra3KM

Our InsightRX team is excited to present three research abstracts at IDWeek 2024, which will be held Oct. 16-19 in Los Angeles. POSTER PRESENTATIONS: 🎙Improved Vancomycin Target Attainment Following a Quasi-Experimental Change in Pharmacokinetic Model for Bayesian Precision Dosing (Poster #1254) 🎙Validating and Comparing the Predictiveness of Cefepime Pharmacokinetic Models Used in Bayesian Dosing (Poster #1253) 🎙Transferring Knowledge from Gentamicin Pharmacokinetics in Neonates to Other Aminoglycosides (Poster #1259) 🗓 Friday, October 18, 2024 🕛 12:15 PM - 1:30 PM PT “We’re excited about presenting our findings at IDWeek and discussing with colleagues how advances in Bayesian MIPD are increasing the accuracy of antibiotic dosing,” said Sirj Goswami, PhD, CEO and cofounder of InsightRX. “Our goal is to advance knowledge and practices surrounding MIPD to improve clinical outcomes and operational efficiency while reducing the incidence of adverse drug events for our customers. These abstracts show where progress is being made and where we’re headed.” Learn more and we look forward to seeing you for the poster presentations: https://hubs.ly/Q02SB9BH0 | #IDWeek2024 #Vancomycin #Pharmacokinetics #PrecisionDosing #BayesianDosing

Unlocking #mRNA-#LNP potential using a novel lipid library combined with innovative #analyticalmethods #Lipidnanoparticles (LNPs) have seen success in their use for #RNAdelivery in various therapies. However, LNPs still exhibit limitations including a tendency to accumulate in the liver and strict requirements for post-formulation quality monitoring. Addressing these challenges holds the key to unlocking the full therapeutic potential of these innovative treatments. Next month, Polyplus now part of Sartorius’ Guillaume Freund (Process Technology Manager) and Sartorius BIA Separations’ Nejc Pavlin (Process Analytics Development Manager) will discuss novel strategies for mRNA-LNP development such as a library of imidazolium-based lipids and liquid #chromatography to ensure the quality, efficacy, and safety of LNPs in various applications. Register for this upcoming #webinar below:

📢 Attention researchers! Invitrogen™ Vivofectamine™ Delivery Solutions have arrived to revolutionize in vivo delivery of nucleic acids with lipid nanoparticles (LNPs)! With their outstanding versatility and safety profile, Vivofectamine products are the ideal choice for both basic researchers and therapeutic development. But that's not all – we also offer custom products and services for supporting therapeutic development. From start to finish, our Vivofectamine Delivery Solutions can provide the delivery system you need for success. Don't miss out on the opportunity to enhance your research, accelerate your project timelines and take it to the next level. Check out Vivofectamine now and unlock new possibilities! 🔗 https://lnkd.in/e3cd5Mrk #delivery #lipidnanoparticles #nucleicacidmedicine #mrnavaccine #mrnatherapeutics #vivofectamine #LNP

Come and meet Véronique Laborde to discuss your API or Polymers development project